The strategy charges fees in line with its similarly distributed peers, priced within the middle quintile.
Fidelity Advisor Biotechnology A FBTAX
- NAV / 1-Day Return 33.27 / −0.06 %
- Total Assets 1.9 Bil
-
Adj. Expense Ratio
- Expense Ratio 0.970%
- Distribution Fee Level Low
- Share Class Type Front Load
- Category Health
- Investment Style Mid Growth
- Min. Initial Investment 0
- Status Open
- TTM Yield 0.94%
- Turnover 73%
USD | NAV as of Oct 02, 2024 | 1-Day Return as of Oct 02, 2024, 10:20 PM GMT+0
Morningstar’s Analysis FBTAX
Will FBTAX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 59.6
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
AbbVie Inc | 18.74 | 348.9 Mil | Healthcare |
Amgen Inc | 9.20 | 171.4 Mil | Healthcare |
Regeneron Pharmaceuticals Inc | 7.47 | 139.2 Mil | Healthcare |
Alnylam Pharmaceuticals Inc | 4.87 | 90.7 Mil | Healthcare |
Vertex Pharmaceuticals Inc | 4.59 | 85.5 Mil | Healthcare |
argenx SE ADR | 3.67 | 68.3 Mil | Healthcare |
Ascendis Pharma AS ADR | 3.53 | 65.7 Mil | Healthcare |
Vaxcyte Inc Ordinary Shares | 2.60 | 48.4 Mil | Healthcare |
Viking Therapeutics Inc | 2.47 | 46.0 Mil | Healthcare |
Cytokinetics Inc | 2.44 | 45.5 Mil | Healthcare |